Browsing Clinical Studies by author "Carreira, Suzanne"
Now showing items 41-47 of 47
-
Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis.
Lambros, MB; Seed, G; Sumanasuriya, S; Gil, V; Crespo, M; et al. (AMER ASSOC CANCER RESEARCH, 2018-11-15)Purpose: Circulating tumor cells (CTCs) have clinical relevance, but their study has been limited by their low frequency.Experimental Design: We evaluated liquid biopsies by apheresis to increase CTC yield from patients ... -
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.
Boysen, G; Rodrigues, DN; Rescigno, P; Seed, G; Dolling, D; et al. (AMER ASSOC CANCER RESEARCH, 2018-11-15)Purpose: CHD1 deletions and SPOP mutations frequently cooccur in prostate cancer with lower frequencies reported in castration-resistant prostate cancer (CRPC). We monitored CHD1 expression during disease progression and ... -
Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
Welti, J; Sharp, A; Yuan, W; Dolling, D; Nava Rodrigues, D; et al. (AMER ASSOC CANCER RESEARCH, 2018-07-01)Purpose: Persistent androgen receptor (AR) signaling drives castration-resistant prostate cancer (CRPC) and confers resistance to AR-targeting therapies. Novel therapeutic strategies to overcome this are urgently required. ... -
Targeting the p300/CBP Axis in Lethal Prostate Cancer.
Welti, J; Sharp, A; Brooks, N; Yuan, W; McNair, C; et al. (AMER ASSOC CANCER RESEARCH, 2021-05-01)Resistance to androgen receptor (AR) blockade in castration-resistant prostate cancer (CRPC) is associated with sustained AR signaling, including through alternative splicing of AR (AR-SV). Inhibitors of transcriptional ... -
The landscape of RNA polymerase II-associated chromatin interactions in prostate cancer.
Ramanand, SG; Chen, Y; Yuan, J; Daescu, K; Lambros, MB; et al. (AMER SOC CLINICAL INVESTIGATION INC, 2020-08-03)Transcriptional dysregulation is a hallmark of prostate cancer (PCa). We mapped the RNA polymerase II-associated (RNA Pol II-associated) chromatin interactions in normal prostate cells and PCa cells. We discovered thousands ... -
TOPARP-B: A Randomised Phase 2 Trial Evaluating Two Doses of Olaparib Against Metastatic Castration-Resistant Prostate Cancer With DNA Repair Gene Aberrations
Hall, E; De Bono, J; Porta, N; Miranda, S; Flohr, P; et al. -
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.
Basu, B; Krebs, MG; Sundar, R; Wilson, RH; Spicer, J; et al. (OXFORD UNIV PRESS, 2018-07-17)BACKGROUND: We have previously shown that raised p-S6K levels correlate with resistance to chemotherapy in ovarian cancer. We hypothesised that inhibiting p-S6K signalling with the dual m-TORC1/2 inhibitor in patients ...